Dextenza With ILUX for Treatment of MGD
Meibomian Gland Dysfunction, Evaporative Dry Eye
About this trial
This is an interventional treatment trial for Meibomian Gland Dysfunction focused on measuring dry eye, meibomian gland dysfunction
Eligibility Criteria
Inclusion Criteria:
A patient's study eye must meet the following criteria to be eligible for inclusion in the study:
- 18 years of age or older
- Evaporative DED with MGD and clinically significant inflammation
- Willing and able to comply with clinic visits and study related procedures
- Willing and able to sign the informed consent form
Exclusion Criteria:
A patient who meets any of the following criteria will be excluded from the study:
- Patients under the age of 18.
- Pregnancy (must be ruled out in women of child-bearing age with pregnancy test)
- Active infectious systemic disease
- Active infectious ocular or extraocular disease
- Altered nasolacrimal flow of either acquired, induced, or congenital origin
- Hypersensitivity to dexamethasone
- Patient being treated with either topical, oral, or intravenous steroids
- Patients with severe disease that warrants critical attention, deemed unsafe for the study by the investigator
Sites / Locations
- Warrenville EyeCare & LASIK
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Active Comparator
Sham Comparator
Dexamethosone intracanalicular insert
Group 1: Prednisolone actetate 1%
Group 2: Sham dilation
All 30 eyes will undergo iLUX MGD Treatment System for the treatment of evaporative DED secondary to MGD. Patients will have their most symptomatic eye selected to receive the dexamethasone intracanalicular insert at the day of the iLUX MGD Treatment System (study eye).
15 fellow eye will undergo iLux and receive topical prednisolone acetate 1% on a 4,3,2,1 taper for 30 days.
15 fellow eye will undergo ILux and receive punctal "sham" dilation (control eye).